Zimmer Biomet Holdings (NYSE:ZBH) : 14 Wall Street analysts covering Zimmer Biomet Holdings (NYSE:ZBH) believe that the average level the stock could reach for the short term is $128.57. The maximum price target given is $135 and the minimum target for short term is around $105, hence the standard deviation is calculated at $8.97.
Other Equity analysts have also commented on the company shares. Guggenheim Securities initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH). The shares have now been rated Neutral by the stock experts at the ratings house. The rating by the firm was issued on June 9, 2016.
Zimmer Biomet Holdings (NYSE:ZBH): stock turned positive on Thursday. Though the stock opened at $119.38, the bulls momentum made the stock top out at $120.92 level for the day. The stock recorded a low of $119.155 and closed the trading day at $120.92, in the green by 1.93%. The total traded volume for the day was 1,941,892. The stock had closed at $118.63 in the previous days trading.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Collins Tony W., officer (VP, Controller and CAO) of Zimmer Biomet Holdings, Inc., had unloaded 3,611 shares at an average price of $116.43 in a transaction dated on June 14, 2016. The total value of the transaction was worth $420,429.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.